Is the music still playing in 2016 for our dancing unicorns?
A shortage of liquidity opportunities is leaving tech unicorns with paper valuations that late-stage private financiers are now less eager to cleanly finance.
Michael Gladstone
Michael Gladstone is a principal with Atlas Venture and focuses on new platform company creation and operations. Michael has been involved in building several Atlas Venture-originated companies, including Spero Therapeutics, Padlock Therapeutics, and Surface Oncology. He has also been closely involved with Atlas’s immuno-oncology investments CoStim Pharmaceuticals (acquired by Novartis) and Unum Therapeutics.